ArticleClinical and translational gastroenterology2017
Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease.
Article in Clinical and translational gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Lymphocyte subsets for predicting inflammatory bowel disease progression and treatment response: a systematic review.Frontiers in immunology · 2024Pooled it
- Comparative Efficacy and Immunogenicity of Infliximab and Adalimumab in Crohn's Disease: A Prospective Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
- Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation.Diagnostics (Basel, Switzerland) · 2025Article
- Establishment and internal validation of a model to predict the efficacy of Adalimumab in Crohn's disease.Scientific reports · 2025Article
- Infliximab Limits Injury in Myocardial Infarction.Journal of the American Heart Association · 2024Article
- Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study.Frontiers in pharmacology · 2023Article
- Precision medicine and drug optimization in adult inflammatory bowel disease patients.Therapeutic advances in gastroenterology · 2023Review
- Serum Calprotectin as a Blood-Based Biomarker for Monitoring Knee Osteoarthritis at Early but Not Late Stages.Cartilage · 2021Article
- Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine.Expert review of clinical immunology · 2021Review
- Evidence for tmTNF reverse signalingiScience · 2021Article
- TNF-α Differentially Regulates Cell Cycle Genes in Promyelocytic and Granulocytic HL-60/S4 Cells.G3 (Bethesda, Md.) · 2019Article
- The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study.Gastroenterology and hepatology from bed to bench · 2019Review
- An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients.United European gastroenterology journal · 2018Article
- Inducible nitric oxide synthase as a potential blood-based biomarker in inflammatory bowel diseases.Gastroenterology and hepatology from bed to bench · 2018Article
- Apoptosis markers of circulating leukocytes are associated with the clinical course of inflammatory bowel disease.Gastroenterology and hepatology from bed to bench · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAnti-tumor necrosis factor (TNF)-α agents like Infliximab (IFX) are effective in the treatment of inflammatory bowel diseases (IBDs) and are widely used. However, a considerable number of patients do not respond or lose response to this therapy. Preliminary evidence suggests that transmembrane TNF-α (tmTNF-α) might be linked to response to IFX by promoting reverse signaling-induced apoptosis in inflammatory cells. The main aim of this study was the evaluation of this hypothesis in primary IFX non-responders.
methodsA total of 47 IFX naive IBD patients were included in the study. Blood samples were taken before the start of IFX therapy (at week 0) and after induction therapy (at week 14). Endoscopic disease activity and markers of inflammation at baseline and at week 14 were used to evaluate response. Baseline soluble TNF-α (sTNF-α), percentage of circulating TNF-α positive cells, mean fluorescence intensity (MFI) of tmTNF-α, and apoptosis rate at week 14 in the peripheral blood mononuclear cells (PBMCs) were evaluated in IFX responders and non-responders.
resultsMean sTNF-α was not significantly different in responders compared to non-responders (P=0.13). Mean percentage of tmTNF-α bearing lymphocytes and monocytes was higher in the PBMCs of responders (P=0.05 and P=0.014, respectively). Mean MFI of tmTNF-α in circulating lymphocytes and monocytes was greater in responders (P=0.002 and P<0.001, respectively). Moreover, the mean percentage of apoptosis in PBMCs was significantly greater in responders compared to non-responders (P=0.002).
conclusionsThe percentage of tmTNF-α bearing lymphocytes and monocytes and the intensity of tmTNF-α in the circulating leukocyte population of IBD patients was directly related to primary response to IFX. This was likely due-as assessed by the apoptosis rate-to promotion of inflammatory cell death. Thus, our data suggest that peripheral leukocytes could in principle be used for predicting primary response to IFX in IBD patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.